Stéphane van Rooijen


Stephane van Rooijen (MD, MBA) is a general management biotech executive with in-depth experience in life sciences working across European and North American organizations. He studied medicine at KU Leuven and obtained an MBA at Erasmus University Rotterdam and Georgetown University, Washington DC. He joined Dynacure in 2016 as Chief Executive Officer.

Stephane started his career at Arthur D. Little on the strategy consultant team. After joining Genzyme Corporation (2004, Amsterdam/Brussels) and working in business development and finance, he became the European Cardiovascular Business Unit Leader, where he managed cross functional business unit teams and early and late stage portfolios, launched novel products, and managed P&Ls. In 2012 he joined Viropharma (London) as a member of Viropharma’s European Business Council and global pipeline project team, where he was responsible for leading the company’s main European commercial program, Cinryze (orphan drug indicated for hereditary angioedema), building infrastructure, driving geographic expansion and partnerships, and supporting R&D pipeline development. In 2014, as founding CEO of Confo Therapeutics (VIB-VUB spin-off), he set up the company, raised funding, recruited an outstanding team, and led the companies’ expansion to build a portfolio of drug development programs.